Xerion Limited is an Australian-based specialty pharmaceutical company focused on revolutionising standard of care in dermatology through the development of innovative therapies.

The company’s product portfolio includes a robust pipeline of dermatological products being developed specifically for the US prescription market. Xerion has already launched over the counter (OTC) products broadly ranged in pharmacies in Australia, New Zealand and sold online in the USA. nailKALM is proven and TGA approved to treat fungal nail disease, and early clinical evidence indicates potential for the treatment of acne, atopic dermatitis, psoriasis, rosacea and actinic keratosis (pre-basal cell carcinoma).

Xerion Limited also has the exclusive commercial license to the PUFAcoatTM technology developed by Professor Robert Gibson and Dr Ge Liu of the School of Agriculture, Food and Wine, University of Adelaide, which has the ability to transform certain aspects of the personalised nutrition market. The technology allows simple, accessible, personalized determination of an individual’s fatty acid profile to help improve their health and achieve their wellness goals. One application for this technology is its utility as a companion diagnostic tool for the high value consumer supplement market for which we have a distribution agreement with BASF, a large global player.

The company’s product portfolio includes proprietary algae bioactives and TGA approved anti-fungal products:

AMYCOT®: algal complex mix of bioactives with anti-fungal, anti-bacterial, anti-inflammatory and skin-repair properties.
KALM: Xerion’s lead product, a topical anti-fungal product line.
PUFAcoat: a proprietary dried blood spot (DBS) which stabilises fatty acids for long periods of time in ambient conditions facilitating the accurate measurement of fatty acids and is a useful tool in determining the Omega 3 Index.

Xerion has a robust product pipeline and research partnerships to extend its product range and indications.

Board Of Directors

Andrew Monk

Chairman

Andrew is a seasoned Chairman of public corporations involving restructures, growth phase, mergers and acquisitions. He has extensive technical experience in standards setting and regulations across agrifood, health/wellness and cosmetics sectors. He has a BSc, PhD and is Adjunct Ass. Prof. at University of New England Armidale School of Law.

Peter Streader

Non-Executive Director

Peter has a legal background and is an experienced company Director and Chairman. He has helped form, develop and manage a number of public and private domestic and international companies. Peter holds a Bachelor of Law from University of Melbourne and was a Fellow of the AICD for 18 years.

Tim Cushway

Non-Executive Director

Tim is qualified with a Bachelor of Science and an experienced pharmaceutical professional with over 20 years in management, clinical development, medical affairs, regulatory, marketing and sales. Based in Singapore he is also experienced in working with multi-cultural teams

George Su

Non-Executive Director

Mr Su headed CITIC Securities Australian Operation between 2009 and 2013 with special focus on cross border transactions between Australia and China. Mr Su currently serves on ASX listed boards including Oriental Technology Investment Co Ltd and YPB Group.

Daniel P Goldman

Managing Director

Danny has extensive operational and financial expertise in a number of corporate segments. He has been CFO of a number of listed and private companies as well as spending time at Ernst & Young Chartered Accountants. Danny is a qualified Chartered Accountant and holds degrees in Accounting Science and Commerce.

Jeremy Keane

Non-Executive Director

Jeremy is an experienced NED and MD with extensive experience in the human services, healthcare pharmaceutical and medical device industries. He has demonstrated capability to rapidly and profitably grow healthcare organisations through both the execution of organic and M&A based growth strategies. He is a strong administrator skilled in business strategy development & execution, M&A and company directorship. He has a B. Physio, MBA and is a Graduate of the AICD.

Management

Dr Leodevico (Vic) Ilag

Chief Scientific Officer

Vic has more than 20 years biotech experience serving in senior executive roles in leading biotech companies, in Australia, Europe and the USA. He has also co-founded a number of start-up companies. Vic has a PhD in Microbiology/Immunology and done postdoctoral studies in structural biology.

Dr Michèle Stokes

Chief Operating Officer

Michèle has 17 years of industry experience in pharmaceutical development and manufacturing, leading teams through growth in Europe, US and across Asia Pacific. Michèle has a Bachelor’s degree and PhD in Cell & Molecular Biology, with several publications in Endocrinology and is an AICD graduate.

Sharyn Cunningham

Chief Finance Officer & Co-Company Secretary

Sharyn is an experienced Chartered Accountant with both large public and small company experience. She has previously worked with Shell Australia and Grant Thornton.

Jeanette Lodge

Chief Regulatory Officer

Jeanette has Masters in Medical Science and more than 23 years of industry experience in regulatory affairs, medical writing and quality management systems. She has held positions in a global healthcare company and has effective working relationships with TGA and Medsafe.

Andres Monroy Cepeda

Head Of Manufacturing & Quality Assurance

Andres is an experienced pharmaceutical manufacturing and QA specialist with 15 years in operations, quality & compliance. His experience spans both private and public companies in the healthcare, pharmaceutical and medical device industries globally. Andres possesses a master of App.Sc. and an MBA.

AMYCOT®

Xerion’s first bioactive ingredient is AMYCOT®, an antimicrobial extract derived through a proprietary process from the microalgae Arthrospira maxima, that has a number of activities including:

anti-fungal (specific action against a major structural component of fungi cell walls)
anti-bacterial (against gram positive bacteria)
anti-viral (against Papilloma and Herpes simplex viruses)
anti-inflammatory
skin repair

AMYCOT® may therefore be regarded as a product platform and the first products to be commercialised are based primarily on AMYCOT®’s fungicidal activity under the brand Amycot calmagen® for KALM® with additional anti-inflammatory and skin repair benefits.

1. Manoj Parekh, Girisha Ramaiah, Prachi Pashilkar, Ranjani Ramanujam, Peter Johnston and Leodevico L. Ilag (2017) A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis. BMC Complementary and Alternative Medicine 17:464. DOI 10.1186/s12906-017-1970-2

2. Ilag LL (2018) Leodevico L Ilag (2018) Ringworm Disease – Causes, Diagnosis and Treatment: AMYCOT®, a Novel Natural Treatment for Ringworm and other Tinea Infections. Journal of Dermatology and Clinical Research 6(1):1114

PUFAcoat

Xerion has acquired the exclusive license in Australia and a number of other countries to the PUFAcoat technology from world leading lipids and nutrition researcher Prof Robert Gibson of the FOODplus Research Centre at the University of Adelaide.

The PUFAcoat protection system comprises a combination of protectants on a defined collection matrix. PUFAcoat can protect against the oxidation of long chain polyunsaturated fatty acids (LCPUFA) in blood spots at ambient temperature for at least 2 months. PUFAcoat was found to prevent any significant loss in the level of the two most important omega 3 fatty acids, EPA and DHA, in blood spots following up to 2 months of storage at room temperature.

1. Ge Liu, Beverly Sara Mühlhäusler, Robert Alan Gibson (2014) A method for long term stabilisation of long chain polyunsaturated fatty acids in dried blood spots and its clinical application. Prostaglandins, Leukotrienes and Essential Fatty Acids 91:251–260. http://dx.doi.org/10.1016/j.plefa.2014.09.009

2. Ge Liu, Beverly Sara Mühlhäusler, and Robert Alan Gibson (2015) Evaluation of contamination associated with current blood spot technology for determining the fatty acid status of individuals. European Journal of Lipid Science and Technology 117(8):1280-1286. https://doi.org/10.1002/ejlt.201400470

Bioactive New Product Development (NPD) Platform

Xerion’s Bioactive NPD platform integrates different generic and proprietary technologies from the discovery of bioactives through clinical validation up to a new marketable product.

In addition to Xerion’s existing product range within the marketplace, the Company will be developing new product initiatives that aim to improve the quality of life of people, world-wide.

1. Leodevico L Ilag (2018) Botanicals and its extracts: A new drug discovery and development paradigm for chronic and age-related illnesses. Med Res Innov 2(1): 1-3. doi: 10.15761/MRI.1000131

2. Leodevico L Ilag (2018) Are Long-Chain Polyunsaturated Fatty Acids the Link between the Immune System and the Microbiome towards Modulating Cancer? Medicines 5(3):102. http://doi.org/10.3390/medicines5030102

Dermatology Product Pipeline

AMYCOT® is the basis for the different dermatological products under development including expanding the KALM range of anti-fungal products.

PUFAcoat Dried Blood Spot Technology

Revolutionary precision dried blood spot technology that accurately measures fatty acids in blood and other biological fluids.

Xerion Limited is an Australian public unlisted specialty pharmaceutical company focused on the development of 5 new products for the US prescription market. Xerion has great financial prospects, and immense upside potential through their pipeline of dermatological products.

Xerion has two proprietary technology platforms with products commercialised from each in the global OTC and personalised medicine markets

KALM: a range of OTC dermaceutical products featuring a key anti-fungicidal ingredient, AMYCOT®. nailKALM® is Xerion’s flagship product.
PUFA: dried blood spot (DBS) test kits for consumers and healthcare professionals to test fatty acid levels, including omega-3 levels.

Key Company Highlights

Leading brand (nailKALM®) with strong IP protection through internationally granted patents and recently ranged in all Chemist Warehouse stores.
Very high product efficacy with TGA approval secured to treat fungal infections.
Competitive advantage with natural active ingredient and zero toxicity.
Clearly differentiated from the competition through ease of use (no filing necessary) and efficacy.
Clear path to take AMYCOT® to the US as a prescription nail fungal drug.
Large global markets including nail fungus (US$1bn), acne (US$1.2bn), psoriasis(US$6.6bn), atopic dermatitis (US$1.7bn+) and actinic keratosis (US$2bn).

AS SEEN ON

The Company has a highly experienced Board of Directors and Management comprising the following personnel:

Board Of Directors

Andrew Monk

Chairman

Peter Streader

Non-Executive Director

Tim Cushway

Non-Executive Director

George Su

Non-Executive Director

Daniel P Goldman

Managing Director

Jeremy Keane

Non-Executive Director

Management

Dr Leodevico (Vic) Ilag

Chief Scientific Officer

Dr Michèle Stokes

Chief Operating Officer

Sharyn Cunningham

Chief Finance Officer & Co-Company Secretary

Jeanette Lodge

Chief Regulatory Officer

Andres Monroy Cepeda

Head Of Manufacturing & Quality Assurance

AMYCOT®

PUFAcoat

Bioactive New Product Development (NPD) Platform

NaiKALM

PUFACoat

Dermatology Product Pipeline

PUFAcoat Dried Blood Spot Technology

Xerion Limited is an Australian public unlisted specialty pharmaceutical company focused on the development of 5 new products for the US prescription market. Xerion has great financial prospects, and immense upside potential through their pipeline of dermatological products.

Xerion has two proprietary technology platforms with products commercialised from each in the global OTC and personalised medicine markets

Key Company Highlights